Papers matching “alternative complement pathway” 9
Not finding it? Sign in to also search OpenAlex live.
-
Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
Morag Griffin, Richard J. Kelly, Mathilde Gavillet, Petra Muus, Britta Hoechsmann, W. Jason Cummings, +4 more
4citations -
Apply-PNH: Analysis of complement pathway biomarkers provides evidence for pharmacodynamic response in PNH patients who receive oral iptacopan monotherapy versus continuing anti-C5 therapy2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Richard Kelly, Austin Gladston Kulasekararaj, Alexander Röth, Phillip Scheinberg, Yasutaka Ueda, +4 more
0citations -
IMAGINATION: A Global Phase 3 Trial of RO7434656, an Antisense Oligonucleotide Inhibitor of Complement Factor B, in IgA Nephropathy2023 Journal of the American Society of Nephrology conference-abstract Medicine Renal Diseases and Glomerulopathies Open access
Jonathan Barratt, Jürgen Floege, Vishal Duggal, Nadine Schmit, Jeannette Lo, Brad H. Rovin
4citations -
The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Anna Gayà, Morag Griffin, Bing Han, Austin Gladston Kulasekararaj, Jaroslaw Pawel Maciejewski, +11 more
0citations -
Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, J Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
2citations -
Long-term safety and efficacy of iptacopan in patients with paroxysmal nocturnal hemoglobinuria: 4- and 5-year follow-up of patients from Phase 2 studies who entered the roll-over extension program
Antonio Maria Risitano, Camilla Frieri, Bor‐Sheng Ko, Lily Wong Lee Lee, Alexander Röth, Flore Sicre de Fontbrune, +8 more
0citations -
Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial
Antonio Maria Risitano, Austin Gladston Kulasekararaj, Alexander Roeth, Phillip Scheinberg, Yutaka Ueda, Eros Di Bona, +29 more
14citations
9 results